EP0689547A4 - Klonierter menschlicher alpha1c-adrenergischer rezeptor - Google Patents

Klonierter menschlicher alpha1c-adrenergischer rezeptor

Info

Publication number
EP0689547A4
EP0689547A4 EP94912209A EP94912209A EP0689547A4 EP 0689547 A4 EP0689547 A4 EP 0689547A4 EP 94912209 A EP94912209 A EP 94912209A EP 94912209 A EP94912209 A EP 94912209A EP 0689547 A4 EP0689547 A4 EP 0689547A4
Authority
EP
European Patent Office
Prior art keywords
adrenergic receptor
cloned human
alpha1c
alpha1c adrenergic
cloned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94912209A
Other languages
English (en)
French (fr)
Other versions
EP0689547A1 (de
Inventor
Marvin L Bayne
Bradley V Clineschmidt
Catherine D Strader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0689547A1 publication Critical patent/EP0689547A1/de
Publication of EP0689547A4 publication Critical patent/EP0689547A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP94912209A 1993-03-15 1994-03-10 Klonierter menschlicher alpha1c-adrenergischer rezeptor Withdrawn EP0689547A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3284993A 1993-03-15 1993-03-15
US32849 1993-03-15
PCT/US1994/002609 WO1994021660A1 (en) 1993-03-15 1994-03-10 Cloned human alpha1c adrenergic receptor

Publications (2)

Publication Number Publication Date
EP0689547A1 EP0689547A1 (de) 1996-01-03
EP0689547A4 true EP0689547A4 (de) 1998-10-28

Family

ID=21867151

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94912209A Withdrawn EP0689547A4 (de) 1993-03-15 1994-03-10 Klonierter menschlicher alpha1c-adrenergischer rezeptor

Country Status (5)

Country Link
EP (1) EP0689547A4 (de)
JP (1) JPH08508163A (de)
AU (1) AU685789B2 (de)
CA (1) CA2158345A1 (de)
WO (1) WO1994021660A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE663014T1 (de) * 1992-09-25 1996-10-10 Synaptic Pharmaceutical Corp., Paramus, N.J. Für menschliche alpha-1-adrenerge rezeptoren kodierende dns und ihre verwendung.
US5403847A (en) * 1992-11-13 1995-04-04 Synaptic Pharmaceutical Corporation Use of α1C specific compounds to treat benign prostatic hyperlasia
US5578611A (en) * 1992-11-13 1996-11-26 Synaptic Pharmaceutical Corporation Use of α-1C specific compounds to treat benign prostatic hyperplasia
US6015819A (en) 1992-11-13 2000-01-18 Synaptic Pharmaceutical Corporation Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
US5952351A (en) * 1995-02-23 1999-09-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6096763A (en) * 1995-02-23 2000-08-01 Merck & Co., Inc. α1a adrenergic receptor antagonists
US5668148A (en) * 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
US5661163A (en) * 1995-06-07 1997-08-26 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
US5620993A (en) * 1995-06-07 1997-04-15 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
US5807856A (en) * 1995-11-15 1998-09-15 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonist
CN100575368C (zh) * 2004-08-04 2009-12-30 积水化学工业株式会社 聚乙烯醇缩醛树脂的制造方法、聚乙烯醇缩丁醛树脂、以及被酯化的聚乙烯醇树脂的制造方法
WO2006021344A1 (en) * 2004-08-27 2006-03-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with alpha-1a adrenergic receptor (adra1a)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016213A1 (en) * 1991-03-20 1992-10-01 Merck & Co., Inc. Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen
WO1993023038A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. 17-AMINO SUBSTITUTED 4-AZASTEROID 5α-REDUCTASE INHIBITORS
WO1994008040A1 (en) * 1992-09-25 1994-04-14 Synaptic Pharmaceutical Corporation Dna encoding human alpha 1 adrenergic receptors and uses thereof
WO1994010989A1 (en) * 1992-11-13 1994-05-26 Synaptic Pharmaceutical Corporation Use of alpha-1c specific compounds to treat benign prostatic hyperplasia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016213A1 (en) * 1991-03-20 1992-10-01 Merck & Co., Inc. Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen
WO1993023038A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. 17-AMINO SUBSTITUTED 4-AZASTEROID 5α-REDUCTASE INHIBITORS
WO1994008040A1 (en) * 1992-09-25 1994-04-14 Synaptic Pharmaceutical Corporation Dna encoding human alpha 1 adrenergic receptors and uses thereof
WO1994010989A1 (en) * 1992-11-13 1994-05-26 Synaptic Pharmaceutical Corporation Use of alpha-1c specific compounds to treat benign prostatic hyperplasia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRUNO J.F. ET AL.: "Molecular cloning and sequencing of a cDNA encoding a human alpha1A adrenergic receptor.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 179, no. 3, 30 September 1991 (1991-09-30), pages 1485 - 1490, XP002059308 *
HARISAWA A.: "Cloning, functional expression and tissue distribution of human cDNA for the alpha1C-adrenergic receptor.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 195, no. 2, 15 September 1993 (1993-09-15), pages 902 - 909, XP002059309 *
LEPOR H ET AL: "THE ALPHA-ADRENOCEPTOR SUBTYPE MEDIATING THE TENSION OF HUMAN PROSTATIC SMOOTH MUSCLE", THE PROSTATE, vol. 22, no. 4, 16 June 1993 (1993-06-16), pages 301 - 307, XP002047748 *
MELLIN T N ET AL: "AZASTEROIDS AS INHIBITORS OF TESTOSTERONE 5ALPHA-REDUCTASE IN MAMMALIAN SKIN", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 44, no. 2, February 1993 (1993-02-01), pages 121 - 131, XP002028037 *
SCHWINN D A & LOMASNEY J W: "Pharmacological characterization of cloned alpha 1-adrenoceptor subtypes: selective antagonists suggest the existence of a fourth subtype", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 227, no. 4, 1 December 1992 (1992-12-01), pages 433 - 436, XP002075428 *
See also references of WO9421660A1 *

Also Published As

Publication number Publication date
JPH08508163A (ja) 1996-09-03
WO1994021660A1 (en) 1994-09-29
CA2158345A1 (en) 1994-09-29
AU685789B2 (en) 1998-01-29
AU6445394A (en) 1994-10-11
EP0689547A1 (de) 1996-01-03

Similar Documents

Publication Publication Date Title
HU9603525D0 (en) Vironectin receptor antagonists
EP0822814A4 (de) ALPHA 1a ADRENERGISCHE REZEPTORANTAGONISTEN
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
EP0721350A4 (de) Intrazelluläre immunisierung
EP0828751A4 (de) Humaner neuropeptidrezeptor
GB9501343D0 (en) Shoulder prothesis
PL314120A1 (en) B-adrenergic antagonists
EP0833637A4 (de) Alpha 1a adrenergischer rezeptorantagonist
AP9400636A0 (en) Endothelin receptor antagonist s
EP0831823A4 (de) ALPHA 1a ADRENERGISCHE REZEPTOR-ANTAGONISTEN
EP0755392A4 (de) Alpha1c-adrenergische rezeptorantagonisten
EP0853629A4 (de) Hepadnavirus-rezeptor
EP0689547A4 (de) Klonierter menschlicher alpha1c-adrenergischer rezeptor
AU119392S (en) Orthotic
GB9517098D0 (en) Receptor
AU647560B2 (en) Human interleukin-5 receptor
EP0542920A4 (en) Cannabinoid receptor
EP0831824A4 (de) ALPHA 1a ADRENERGISCHE REZEPTORANTAGONISTEN
EP0792282A4 (de) Menschlicher Endothelin-Bombesin Rezeptor
EP0773959A4 (de) Adrenergischer rezeptor
ZA945372B (en) Tyrosine kinase receptor
EP0853479A4 (de) Alpha 1b adrenergischer rezeptorantagonisten
EP0716694A4 (de) Rezeptor für menschliches glucagon-ähnliches 1 peptid
GB9318105D0 (en) Receptor action
EP0832124A4 (de) Menschlicher aminrezeptor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951016

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/12

A4 Supplementary search report drawn up and despatched

Effective date: 19980910

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20010426

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010907